I agree that leronlimab has no SAEs at this point, compared to other CCR5 inhibitors and thus the possible deleterious effects in the study shown may well be because of the toxicity of the other CCR5 inhibitors. However, the effect of CCR5 inhibition and the inflammatory response is subject to much conjecture at this point. Yes, an immune system on overdrive causes much damage to patients with the flu; but, to just propose that leronlimab will mitigate this without proper pre-clinical studies, etc., is irresponsible.